Robert Shenkar

Research Associate Professor

University of Chicago

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Robert Shenkar is a Research Associate Professor at The University of Chicago, USA. His research primarily focuses on the pathophysiology and clinical management of cerebral cavernous malformations and other neurovascular diseases. Recent publications include systematic reviews and experimental studies examining the role of microRNAs, inflammatory mechanisms, and treatment strategies involving mTORC1 inhibitors and propranolol.

Articles (12)

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (4)

Stephanie Hage

University of Chicago Medicine

UNITED STATES

View details

Rhonda Lightle

University of Chicago

UNITED STATES

View details

Romuald Girard

Research Assistant Professor

University of Chicago

UNITED STATES

View details

Kelly Flemming

Associate Professor

Mayo Clinic Minnesota

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Robert Shenkar

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

A Systematic Review of MicroRNAs in Hemorrhagic Neurovascular Disease: Cerebral Cavernous Malformations as a Paradigm

Inflammatory Mechanisms in a Neurovascular Disease: Cerebral Cavernous Malformation

Impact of socioeconomics and race on clinical follow-up and trial enrollment and adherence in cerebral cavernous malformation

Brain tumor like vascular anomaly: Pragmatic management

Multidisciplinary coordinated care of hereditary hemorrhagic telangiectasia (Osler–Weber–Rendu disease)

mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice

Propranolol as therapy for cerebral cavernous malformations: a cautionary note

Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans

A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH)

Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models

Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu.

Novel Murine Models of Cerebral Cavernous Malformations

Collaborators (4)

Stephanie Hage

Rhonda Lightle

Romuald Girard

Kelly Flemming

Make your next move.